Eagle Global Advisors LLC Has $408,000 Position in Opko Health, Inc. (NASDAQ:OPK)

Eagle Global Advisors LLC continued to hold its stake in Opko Health, Inc. (NASDAQ:OPK) during the second quarter, Holdings Channel reports. The fund owned 62,000 shares of the biotechnology company’s stock at the end of the second quarter. Eagle Global Advisors LLC’s holdings in Opko Health were worth $408,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. AQR Capital Management LLC bought a new stake in Opko Health during the fourth quarter valued at about $105,000. Comerica Bank bought a new stake in Opko Health during the fourth quarter valued at about $117,000. Timber Hill LLC bought a new stake in Opko Health during the first quarter valued at about $114,000. World Asset Management Inc boosted its stake in Opko Health by 23.6% in the first quarter. World Asset Management Inc now owns 15,176 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 2,900 shares in the last quarter. Finally, IFC Holdings Incorporated FL boosted its stake in Opko Health by 15.9% in the first quarter. IFC Holdings Incorporated FL now owns 15,339 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 2,100 shares in the last quarter. 23.65% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Opko Health, Inc. (NASDAQ:OPK) opened at 6.20 on Friday. The company’s market cap is $3.47 billion. Opko Health, Inc. has a 1-year low of $5.99 and a 1-year high of $12.15. The firm’s 50-day moving average is $6.48 and its 200 day moving average is $7.40.

Opko Health (NASDAQ:OPK) last issued its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.02. The firm had revenue of $296.10 million during the quarter, compared to the consensus estimate of $313.36 million. Opko Health had a negative return on equity of 2.13% and a negative net margin of 3.60%. The firm’s revenue for the quarter was up 1.8% compared to the same quarter last year. During the same period last year, the business earned ($0.02) earnings per share. Equities analysts expect that Opko Health, Inc. will post ($0.20) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “[[title]]” was originally reported by [[site]] and is the sole property of of [[site]]. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at [[permalink]].

Several research firms recently issued reports on OPK. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $8.00 price target on shares of Opko Health in a report on Thursday, July 27th. Barrington Research upped their price target on shares of Opko Health to $11.00 and gave the company an “outperform” rating in a report on Tuesday, July 18th. Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $19.50 price target on shares of Opko Health in a report on Tuesday, June 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. Opko Health has an average rating of “Buy” and an average price target of $14.72.

In related news, CEO Phillip Md Et Al Frost acquired 207,700 shares of the business’s stock in a transaction on Wednesday, May 31st. The stock was bought at an average cost of $6.11 per share, with a total value of $1,269,047.00. Following the completion of the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at $18,751,290.61. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director John A. Paganelli acquired 5,000 shares of the business’s stock in a transaction on Thursday, June 1st. The shares were bought at an average cost of $6.17 per share, with a total value of $30,850.00. Following the completion of the acquisition, the director now owns 350,340 shares of the company’s stock, valued at approximately $2,161,597.80. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 2,856,000 shares of company stock valued at $18,990,617. 40.19% of the stock is owned by company insiders.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health, Inc. (NASDAQ:OPK).